How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
The fair value estimate for Ligand Pharmaceuticals has been nudged higher, moving from US$243.44 to US$244.56 in the latest analyst update. That shift is closely tied to refreshed views on QTORIN and the broader royalty portfolio, where recent Phase 3 SELVA data, royalty revenue tracking and revised peak sales scenarios are feeding into richer price target work. As you read on, you will see how these moving pieces shape the evolving narrative around Ligand and what to watch as new data points come through. Stay updated as the Fair Value for Ligand Pharmaceuticals shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Ligand Pharmaceuticals. What Wall Street Has Been Saying ?? Bullish Takeaways H.C. Wainwright raised its Ligand price target to US$239 from US$231 after the Phase 3 SELVA trial met its primary endpoint in microcystic lymphatic malformations, and highlighted that Ligand is entitled to QTORIN royalt
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says [Yahoo! Finance]Yahoo! Finance
- Ligand Pharmaceuticals (LGND) is now covered by Bank of America Corporation. They set a "buy" rating and a $244.00 price target on the stock.MarketBeat
- Ligand to Participate in March Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Ligand to Participate in March Investor ConferencesGlobeNewswire
- Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
LGND
Earnings
- 2/26/26 - Beat
LGND
Sec Filings
- 3/13/26 - Form 4
- 3/11/26 - Form 144
- 3/6/26 - Form 4
- LGND's page on the SEC website